- Home
- ISPR vs IFRX Comparison
ISPR vs IFRX Comparison
Compare ISPR & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPR
- IFRX
- Stock Information
- Founded
- ISPR 2010
- IFRX 2007
- Country
- ISPR United States
- IFRX Germany
- Employees
- ISPR N/A
- IFRX N/A
- Industry
- ISPR Medicinal Chemicals and Botanical Products
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- ISPR Health Care
- IFRX Health Care
- Exchange
- ISPR Nasdaq
- IFRX Nasdaq
- Market Cap
- ISPR 91.6M
- IFRX 86.0M
- IPO Year
- ISPR 2023
- IFRX 2017
- Fundamental
- Price
- ISPR $2.17
- IFRX $1.17
- Analyst Decision
- ISPR Strong Buy
- IFRX Strong Buy
- Analyst Count
- ISPR 1
- IFRX 5
- Target Price
- ISPR $7.50
- IFRX $9.80
- AVG Volume (30 Days)
- ISPR 50.3K
- IFRX 7.7M
- Earning Date
- ISPR 11-06-2025
- IFRX 11-10-2025
- Dividend Yield
- ISPR N/A
- IFRX N/A
- EPS Growth
- ISPR N/A
- IFRX N/A
- EPS
- ISPR N/A
- IFRX N/A
- Revenue
- ISPR $118,506,875.00
- IFRX $73,729.00
- Revenue This Year
- ISPR $60.96
- IFRX N/A
- Revenue Next Year
- ISPR $23.96
- IFRX $1,216.24
- P/E Ratio
- ISPR N/A
- IFRX N/A
- Revenue Growth
- ISPR N/A
- IFRX N/A
- 52 Week Low
- ISPR $1.44
- IFRX $0.71
- 52 Week High
- ISPR $6.56
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- ISPR 56.45
- IFRX 43.64
- Support Level
- ISPR $1.85
- IFRX $1.25
- Resistance Level
- ISPR $1.99
- IFRX $1.31
- Average True Range (ATR)
- ISPR 0.23
- IFRX 0.19
- MACD
- ISPR 0.07
- IFRX -0.03
- Stochastic Oscillator
- ISPR 89.13
- IFRX 7.14
About ISPR Ispire Technology Inc.
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping products in the United States, Europe, Canada, and South Africa. Geographically, the company generates the majority of its revenue from Europe.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.